Progressive Pulmonary Fibrosis

Nerandomilast Shows Promise in Slowing Progressive Pulmonary Fibrosis in Autoimmune Disease: Insights from the FIBRONEER-ILD Trial

By MedXY 10/25/2026

The FIBRONEER-ILD trial demonstrates nerandomilast’s potential to slow lung function decline and reduce mortality in patients with autoimmune-related progressive pulmonary fibrosis, with a favorable safety profile.

進行性肺線維症における定量的CT：INBUILD試験サブスタディから得られた知見

news Respiratory

Quantitative Computed Tomography in Progressive Pulmonary Fibrosis: Insights from the INBUILD Trial Sub-Study

By MedXY 10/24/2026

Quantitative CT imaging offers valuable prognostic information and helps assess treatment response in patients with progressive pulmonary fibrosis, supporting better clinical trial outcomes and therapeutic decisions.

Clinical Updates news Respiratory Specialties

Nerandomilast for Idiopathic and Progressive Pulmonary Fibrosis: Phase 3 Trial Insights

By MedXY 08/01/2025

Phase 3 trials demonstrate that nerandomilast, a selective PDE4B inhibitor, significantly slows lung function decline in idiopathic and progressive pulmonary fibrosis over 52 weeks, with manageable safety profiles.